Please use this identifier to cite or link to this item:
|Title:||The role of monoclonal antibody in combination with first-line chemotherapy in Asian patients with advanced non-small cell lung cancer||Authors:||Cho, B.C.
Non-small cell lung cancer
|Issue Date:||Jan-2010||Citation:||Cho, B.C., Kim, J.H., Soo, R.A., Yang, C.-H. (2010-01). The role of monoclonal antibody in combination with first-line chemotherapy in Asian patients with advanced non-small cell lung cancer. Yonsei Medical Journal 51 (1) : 1-8. ScholarBank@NUS Repository. https://doi.org/10.3349/ymj.2010.51.1.1||Abstract:||The strategies of incorporating monoclonal antibodies (MoABs) have now proved efficacy in the first-line treatment of advanced non-small cell lung cancer (NSCLC). These include targeting the vascular endothelial growth factor (VEGF) or epidermal growth factor receptor (EGFR). Bevacizumab is a MoAB targeting the vascular endothelial growth factor (VEGF), an important mediator of new blood vessel formation. Cetuximab is a MoAB directed at EGFR. Binding cetuximab to EGFR blocks signal transduction and promotes receptor internalization and degradation. In this review, we present current data of bevacizumab and cetuximab for the first line treatment of advanced NSCLC. We also refer to their potential for Asian patients with advanced NSCLC in the first-line setting. © Copyright Yonsei University College of Medicine 2010.||Source Title:||Yonsei Medical Journal||URI:||http://scholarbank.nus.edu.sg/handle/10635/116179||ISSN:||05135796||DOI:||10.3349/ymj.2010.51.1.1|
|Appears in Collections:||Staff Publications|
Show full item record
Files in This Item:
There are no files associated with this item.
checked on Nov 16, 2019
WEB OF SCIENCETM
checked on Nov 7, 2019
checked on Nov 8, 2019
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.